Background: Vitiligo is a chronic autoimmune disease, resulting from the destruction of melanocytes and causes depigmentation of the skin. Vitiligo affects approximately 1% of people worldwide and can affect both adults and children, causing marked psychological distress and diminished quality of life. Aims and objectives: To analyse the Efficacy and safety of Tofacitinib in the treatment of vitiligo. Materials and methods: It will be an observational analytical study with longitudinal design. The study will be conducted in Sian Hospital, Bolpur and Santiniketan Medical College and Hospital, Birbhum, West Bengal. The data collection for the study will be done between September 2022 and April 2023. Clinically diagnosed patients of vitiligo, aged 18 years and older, attending the study setting(s) and willing to participate in the study after giving their informed consent, will be considered as study population, with 34 clinically diagnosed patients of vitiligo. Patients were treated with Tofacitinib at 5 mg twice daily for 3 months and efficacy was assessed by score of VASI (Vitiligo Area Scoring Index). Results and observations: The mean age of the patients was 43.34±10.74, about 35.3% belonged to age group 40-49 years, 24(70.59%) patients were male, and 13 (37.5%) patients of vitiligo gave positive family history. About 55.88% patients suffered from general vitiligo, 23.52 % had acrofacial, 8.82% segmental vitiligo and 11.77% suffered from mucosal vitiligo. Regarding efficacy, at base line the score of vitiligo was 25, at 1st follow up it was 22, at 2nd follow up it was 18, at 3rd follow up it was 15, at 4th follow up it was 12 and at 5th follow up it was 8 and only 7(20.59%) patients had experience of adverse effects (mild in nature) as a result from oral treatment with tofacitinib. Conclusion: In our study, JAK inhibitor monotherapy, Tofacitinib appear to be effective and safe. Prospective clinical trials at multiple centres, with large sample size for a long duration and treatment with JAK inhibitors together with or without light exposure/phototherapy may be needed to assess efficacy and safety of Tofacitinib in the treatment of vitiligo.